The study enrolled 680 patients who were randomized after surgery to receive either SOC 66 Gy radiotherapy and cisplatin (100 mg/m2 Q3W for three cycles) or nivolumab 240 mg, followed by SOC ...
Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.
GORTEC Logo (PRNewsfoto/GORTEC) The study evaluated after surgery the addition of nivolumab to standard-of care (SOC) radiotherapy and cisplatin, compared to SOC radiotherapy and cisplatin alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback